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The current trend in medical care in the 21st century is evolving into a minimally invasive specialty.
The interest of Interventional Radiology (IR) in cosmetic is increasing particularly for outsetting patients,
in the treatment of soft tissue vascular malformations, us-guided injections of Botox and varicous veins
management. Advantages of cosmetic IR treatments are many: treatments takes less than an hour and
provides immediate relief of symptoms; no scaring, because the procedure does not require a surgical
incision; an immediate return to normal activity with little or no pain; and high success rate and low
recurrence rate compared to surgery.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.The current trend in medical care in the 21st century is evolving
into a minimally invasive specialty.
The interest of Interventional Radiology (IR) in cosmetic is
increasing particularly for outsetting patients, in the treatment of
soft tissue vascular malformations, us-guided injections of Botox
and varicous veins management. IR is well suited to expand into
this emerging ﬁeld; most interventional radiologists will have the
manual dexterity, anatomical knowledge and image guidance
necessary to perform excellent cosmetic procedures.
Appetite for cosmetic procedures is voracious: there was
a 444% increase between 1997 and 2007 in all cosmetic procedures
performed in the U.S., and the rise in nonsurgical cosmetic proce-
dures soared by 728%.1
For illustrative purposes, it’s necessary treat patients with
varicose veins because their legs are aching and also because they
may be unsightly. And as you treat them, these patients ask for
other cosmetic interventions, such as collagen ﬁllers, Botox injec-
tions, or maybe variations on liposuctions.2 In fact the end result of
venous insufﬁciency is varicose veins, spider veins, and skinciates Ltd. Published by Elsevier Ltchanges of varying severity depending on the severity and chro-
nicity of venous reﬂux.1
We already know how to make our patients feel good, now
we can also learn how to make them look good.1
Interventional radiologists have the ﬁnest skill set in medicine
when it comes to performing minimally invasive procedures, and
these specialists can quickly see their talents blossom in the
cosmetic procedure market space.1
1. Cosmetic interventional radiology in the treatment of soft
tissue venous malformation in adult patient
1.1. Introduction
Vascular lesions of soft tissues are classiﬁed into hemangiomas
and vascular malformation on the basis of their natural history,
cellular turnover, and histology.5
Hemangiomas are benign endothelial cell neoplasms that
appear during infancy and usually have a history of proliferation
followed by spontaneous involution.
Although vascular malformations are congenital, they may not
be seen at birth. The main locations are the head and the neck (40%
of cases), extremities (40%), and trunk (20%) (6).d. All rights reserved.
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enlarge in proportion to the growth of the child unlike
hemangiomas.
Peripheral vascular malformation is treated by surgical resec-
tion, arterial embolization, or direct percutaneous puncture with
embolic material (sclerotherapy).
Vascular malformations have sporadic and chromosomal-
induced errors in endothelial development but demonstrate
normal endothelial turnover and thin-walled dilated channels with
sparse smooth-muscle cells and adventitial ﬁbrosis.
Vascular malformations have a high recurrence rate because
they originate from the mesenchymal cells at an early stage of
embryogenesis. They retain the embryonic growth potential, which
is often represented clinically as recurrence. Some vascular mal-
formations become increasingly destructive as they continue to
grow and progress. Some vascular malformations appear as part of
a familial genetic disorder called angiomatous syndrome. One form
of this syndrome, Rendu–Osler–Weber syndrome, is caused by two
genetic disorders6,7 both of which result in the loss of function of
cell receptors. Rendu–Osler–Weber syndrome usually manifests
with telangiectasia of the skin and mucous membranes(mouth and
gastrointestinal tract). The telangiectasia typically appears during
puberty and causes bleeding.81.2. Classiﬁcation
A classiﬁcation scheme for vascular anomalies based on cellular
features, ﬂowcharacteristics, and clinical behaviour.9Hemangiomas
are divided in simple malformation (capillary malformation) and
combined malformation (arteriovenous ﬁstula, arteriovenous mal-
formation, capillary-venous malformation, capillary-lymphatic-
venous malformation). Also other vascular tumor are divided into
simple malformation (lymphatic malformation, venous malforma-
tion) and combined malformation (lymphatic-venous malforma-
tion, capillary-lymphatic-arterio-venous malformation).1.3. Selection of imaging modalities
Vascular malformations (VMs) can be classiﬁed on hemody-
namics as low-ﬂow and high-ﬂow malformations and on
predominant abnormal vascular channels. Malformations with
arterial components are considered to be high-ﬂow lesions, and
those without arterial components are considered to be low-ﬂow
lesions. Ultrasound (US) is useful to evaluate margins of the mal-
formations but it’s not able to determinate the full extend of VM.4
Doppler US permits real-time analysis of arterial ﬂow and
venous ﬂow and measurement of ﬂow velocities, differentiating
low- from high-ﬂow VMs.10
Contrast-enhanced ultrasound (CEUS) can be helpful to evaluate
low-ﬂow VMs and during percutaneous sclerotherapy to depict
ablation area.11
Multi-detector row CT can evaluate enhancement, presence of
calciﬁcation or thrombus, and the distal run off. Because of its high
temporal resolution, CT is a good tool to evaluate VMs, but has the
disadvantage to exposure to ionizing radiation.4
Magnetic Resonance depicts the full extend of VMs and relation
between VMs and adjacent structures. Spin echo T1 weighted
images are useful to evaluate basic anatomy. STIR and T2 weighted
images can assess the extension of malformations.4 Dynamic
contrast-enhanced MRI is useful to distinguish high-ﬂow from
low-ﬂow VMs.12 Time-resolved MR angiography13,14 could be
a reliable tool for the characterization of VMs with respect to
arterial feeders, nidus size, and venous drainage; its limit is to
depict the small terminal branch of the afﬂuxion artery.Direct percutaneous phlebography and peripheral phlebog-
raphy can be helpful in case of atypical VMs or in presence of
composed or dysmorphic veins.15
Angiography is not relevant for the diagnosis but it’s important
as a precursor to interventional procedures.1.4. Technique
1.4.1. Principles of technique
Sclerotherapy in particular is accepted as independent therapy
for soft tissue vascular malformations. The ﬂow of vascular mal-
formations can be reduced by means of embolotherapy, but such
treatment is usually palliative, because a vascular malformation is
in fact a malformative ﬁeld with multiple arteriovenous ﬁstulas.16
Because vascular malformations are responsive to various
stimuli such as injury and surgical intervention, improper treat-
ment often rapidly stimulates quiescent vascular malformations,
making the condition worse. Hypoxia modulates the expression of
adenosine receptors in human endothelial and smooth-muscle
cells toward an angiogenic phenotype.17 Therefore, complete
destruction of the nidus of a vascular malformation is the only
potential cure. Ameliorating the clinical symptoms can be another
goal in treating problematic vascular malformations.18 Clinical
improvement can be achieved with several courses of
sclerotherapy.19
Although embolotherapy is generally a safe procedure in expe-
rienced hands, it should not be performed unnecessarily, particu-
larly if the symptoms are not severe.20
1.4.2. Injection procedure
Before injection of the sclerosant, the physician should check
the rate of blood ﬂow (ﬂow velocity) in the nidus throughout US
Color Doppler and Power Doppler; the US-guide allows a real-time
controlled injection decreasing the amount of active principle
injected.
Lauromacrogol 400 (Atossisclerol 0,25–3%) is one of the main
agents used for sclerotherapy.
One part of Atossisclerol should be mixed with three parts of
air to maintain a nonionic surfactant effect and the percutaneous
needle insertion into the nidus is US-guided.21
If it is impossible to reach the nidus for some reason, a trans-
arterial, transvenous, or transosseous22 approach is recom-
mended. The physician should be aware that the injection should
be in the nidus or as near to it as possible. Injection of Laur-
omacrogol 400 leads to thrombogenesis as a result of chemical
damage to the vascular wall. The sclerosant should remain only
few minutes into the vessels to prevent a chemical damn. A slow-
ﬂow vascular malformation can usually be successfully treated
with sclerotherapy. If the approach route is free from severe
complication, direct puncture with an 18–22-gauge needle is
recommended. For a small lesion (less than 30 mm in diameter),
only one session is necessary to complete the procedure. Even for
treatment of a vascular malformation without ﬂow, careful
gradual injection (with a 1.0–2.0-mL syringe) with ﬂuoroscopic
guidance is needed to prevent overdose and overﬂow into the
drainage vein.41.5. Effectiveness and complication
Endovascular treatment with sclerotherapy is now well
accepted as ‘independent therapy’ for surgically ‘inaccessible’
lesions and for none to poor surgical candidates with diffuse inﬁl-
trating, extratruncular lesions.
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lesions that extend beyond the deep fascia with involvement of
muscle, tendon and bone.
Among the various embolization and sclerotherapy agents
available, absolute ethanol is recommended as the main sclerosing
agent for surgically inaccessible, diffuse inﬁltrating extratruncular
lesions. Ethanol is the most powerful sclerotherapy agent with
excellent long-term results and outcomes. It also carries the highest
risk of complication and morbidity among the various sclerosing
agents. The presence of sclerotherapy agent in vessels causes
endothelial damage, denaturation of blood proteins, thrombus
formation, and vascular occlusion.19 A 64%–96% response rate,
deﬁned as improvement in symptoms or reduction in the size of the
lesion, has been reported after sclerotherapy of venous
malformations.18
Complication rates ranging from 7.5% to 27.9% have been
reported18; complications include minor skin blisters, skin
necrosis, transient pain, muscle contracture, motor or sensory
nerve injury related to the swelling involved with resultant
nerve compression rather than nontarget embolization of the
vasa nervorum,37 superﬁcial cellulitis, deep vein thrombosis,
pulmonary embolus, and cardiopulmonary collapse. Close
cardiopulmonary monitoring is required for safe administration
of ethanol. Increased pulmonary artery pressure may occur
during ethanol sclerotherapy.8,21 Pulmonary hypertension is
potentially fatal and occurs when ethanol reaches the pulmo-
nary circulation. Cessation of ethanol administration is necessary
to prevent progression to pulmonary spasm and cardiopulmo-
nary arrest. To minimize complications, the minimally effective
dose of ethanol should be administered over multiple treatment
sessions. This approach should minimize the potential for
collateral damage to the surrounding tissues (nerve, vessel,
cartilage, skin and soft tissue). The morbidity of the CVM lesion
should be weighed against the morbidity associated with
ethanol sclerotherapy. In certain situations, an acceptable degree
of collateral damage is necessary for control of a life-threatening
lesion. Periodic follow-up evaluation after treatment is essential
for long-term care. Follow-up should include radiologic evalua-
tion using an appropriate combination of the various non-inva-
sive studies which include Duplex scan, Contrast-enhanced
ultrasound (CEUS), computed tomography and magnetic reso-
nance imaging.
1.6. Conclusions
A new treatment strategy, based on a multidisciplinary
approach, allows a one-day-hospital endovascular therapy to
improve long-term treatment results with reduced morbidity and
recurrence in outsetting patients.
Endovascular therapy is now essential as independent therapy
to surgically ‘inaccessible’ lesions.
2. Intravascular approaches to the treatment of varicose veins
2.1. Introduction
In medical care the current trend is evolving into a mini-
mally invasive specialty. This trend is driven not only by the
physician as one tries to perform procedures that provide less
risk and are quicker to perform, but also by public demand.
Many minimally procedures have entered the ﬁeld of phle-
bology as the use of endoluminal radiofrequency (RF) device or
thermocoagulation with laser. Intravascular laser and RF
devices were developed to thermocoagulate the endothelial
cells producing destruction of the speciﬁc targeted vessel in thetreatment of great saphenas vein (GSV), minimizing surgical
treatment. Approximately 25% of all women and 15% of all men
in North America have some kind of lower extremity venous
insufﬁciency.32.2. Technique
2.2.1. Description of procedure
The course of the great saphenous vein, the femoral vein, and
the saphenofemoral junction will be identiﬁed with the use of
ultrasound in the standing position. Using Doppler skin overlying
the GSV will be marked, and with transillumination the distal
varicosities were marked. After skin preparation and draping,
tumescent anesthesia will be instilled around the course of the GVS
to be treated and in the region of the multiple clusters of varicose
vein. Tumescent anesthesia in a perivascular position serves to
protect perivascular tissues from thermal effects, to decrease the
diameter of vein, and to provide local anesthesia. Trough a sheat
(6–8 F) in the mid thigh over the GSV will be gained the access to
the saphenous. The endoluminal optic ﬁber will be monitored
externally by visualization of the helium: neon aiming beam and
under US guidance.
2.2.2. RF closure
Tissue destruction with RF energy is potentially safer and more
controllable than other mechanisms. The mechanism by which RF
current heats tissue is resistive (or ohmic) heating of a narrow rim
(less than 1 mm) of tissue that is in direct contact with the elec-
trode. Temperature increase remains localized around the active
electrode provided that close, and a stable contact is maintained
between the active electrode and the vessel wall, so this is a rela-
tively safe process. Deeper tissue planes may be slowly heated by
conduction from the small-volume region of heating.
With worldwide clinical experience on thousands of patients
since 1999–2007, GSV’s RF closure is rapidly being added to the
armamentarium of ways to deal with axial venous reﬂux. RF
closure has an efﬁcacy equal to or better than that of ligation and
stripping with less pain, shorter ‘‘sick leave’’, and faster return to
normal activities,25 as demonstrated in all published studies. 90%
of patients resuming normal activities 1–2 days postoperatively
with RF closure performed under local tumescent anesthesia.
2.2.3. Endoluminal/intravascular laser
Endoluminal lasers have been demonstrated to effectively close
axial veins through thermal damage to endothelium with subse-
quent thrombosis and resorption of the damaged vein. Endolumi-
nal laser closure has lower costs and is much quicker with the
speed of pull-back typically 10–20 cm/min. Varicose veins are
marked, tumescent ﬂuid is placed around the vein, and access is
obtained, as previously described. Within a protective sheath
a laser ﬁber (500- to 600-mm) is inserted into the vein. The sheath
is then removed. The laser is activated in a continuous ﬁring mode
with slow mechanical withdrawal at a rate of 1 mm/s. This tech-
nique minimizes pain, maintaining treatment’s efﬁcacy. Intravas-
cular laser treatment (IVL) allows delivery of laser energy directly
into the blood vessel lumen to produce endothelial and vein wall
damage with subsequent ﬁbrosis.2.3. Effectiveness
Endovenous technologies have revolutionized the management
of superﬁcial venous insufﬁciency. The superiority of endovenous
technologies is in terms of efﬁciency, cost, reimbursement, proce-
dure time, and side effect proﬁles.
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sive techniques as saphenous vein ligation and stripping proce-
dures that required hospitalization, signiﬁcant cost, and downtime
as well as more signiﬁcant scarring and other associated parame-
ters of morbidity.
Endovenous laser and radiofrequency technologies have been
shown a comparable both short-term and long-term results, esti-
mated to be between 85 and 90%, highly outperforming those of
previous surgical therapeutic approaches.
In addition, with the introduction of tumescent anesthesia as an
integral part of this procedure have markedly decreased thermal
morbidity associated with these technologies.
IR have revolutionized and improved patient care and outcomes
with the ever-increasing surgical trend of effective minimally
invasive, no downtime procedures that will ultimately lead to
a decreased incidence of sequelae of chronic-venous insufﬁciency
(i.e., pain, ulcers, dermatitis, lipodermatosclerosis) in the ever-
expanding aging population afﬂicted with venous disease.2.4. Complications
If patients are not ambulatory after the procedure and/or if
tumescent anesthesia is not given, complications in the form of
deep vein thrombosis or angiogenesis have been reported.27,282.5. Conclusions
In the past, patients with varicose veins were referred for
surgical stripping, but this invasive procedure is no longer the gold
standard of treatment. Endothermal treatment under ultrasound
guidance, using radiofrequency ablation (RFA) or laser technology,
has become the procedure of choice in selected patients.3 Although
outpatient settings for the minimally invasive treatment of varicose
veins looks to be a solid place to gain a foothold in the cosmetic
medicine market, an appropriate ambience is critical to ensuring
the success of such a venture. The design of a traditional diagnostic
imaging facility is simply not awelcoming environment for patients
concerned with cosmetic appearance.
Interventional radiology has been a ﬁeld that has been marked
by several evolutionary and revolutionary stages1: it’s not the
strongest of the species that survive, or the most intelligent, but the
ones most responsive to change.4
The techniques of endovenous RF or laser ablation or occlusion
offer a less invasive alternative to ligation and stripping as well as
a faster and less expensive method to treat varicose saphenous
trunks and junctions in outsetting patients.
3. The use of Botox for facial rejuvenation in interventional
radiology
3.1. Introduction
Botulinum Toxin Type A is a 150-kD single-chain polypeptide
produced by Clostridium Botulinum and its existence has been
known for centuries. However, its utility as an injectable thera-
peutic agent was only ﬁrst suspected in the late 1970s and early
1980s.28 In 1989, the Food and Drug Administration (FDA) approved
its use for the treatment of strabismus, blepharospasm, and hem-
ifacial spasm. Interest in Botulinum Toxin as a therapeutic agent has
increased over time and truly exploded since the turn of the last
century. The current FDA approved uses for Botulinum Toxin
include the following: temporary improvement in the appearance
of moderate to severe glabelar lines, blepharospasm, cervical dys-
tonia, severe primary axillary hyperhidrosis, and strabismus.The mechanism of action for Botulinum Toxin is through the
inhibition of acetylcholine release from presynaptic neurons at the
neuromuscular junction. This permanently disables the motor end
plate and leads to functional denervation of the muscle.29 Muscle
weakness typically becomes apparent over 3–10 days with an
anticipated duration of effect ranging from 3 to 6 months. The
neuromuscular junction recovers by presynaptic axonal
‘‘resprouting’’ resulting in the formation of new motor end plates
and, in effect ‘‘re-innervation’’ of the muscle.31 Botulinum Toxin
(Botox) is supplied in a vial containing 100 U of vacuum-dried
Clostridium Botulinum Type A neurotoxin complex. Unrecon-
stituted, Botox can be kept frozen for 2 years. It can be used
preserved normal saline to reconstitute Botox. Once recon-
stituted, the manufacturer recommends that it be used within 4 h;
however, some studies have suggested that once reconstituted,
may be frozen, rethawed before injection, and retain its potency
for up to 2 weeks.31
3.2. Technique
The use of Botox for facial rejuvenation has been FDA approved
since 2002.32
There are innumerable chemodenervation protocols for facial
rejuvenation available.33–36 For illustrative purposes, it will be
described a technique for the treatment of frown lines (glabelar
lines).39 Glabelar lines primarily result from contraction of the
corrugators supercilli and procerus muscles. These two muscles
therefore serve as the targets for chemodenervation. The corru-
gators muscle bellies are easily palpated with the patient frowning.
The procerus muscle, while more difﬁcult to palpate, is easily tar-
geted on either side of the nasal bone at the level of the bridge of
the nose. For cosmetic purposes, it can be used 100 units of Botox
in 4 mL of preserved normal saline. This produces a solution with
a concentration of 2.5 units per 0.1 mL. At this concentration,
a volume of 0.04 mL represents each unit of Botox. Under US
guidance between 5 and 7.5 units of Botox are then injected at two
or three sites within the muscle on each side, depending on its
conﬁguration. US guidance minimizes the risk to inﬁltrate nervous
peripheral structure, reducing adverse consequences as eyelid
ptosis. With normal anatomic variation, the injection pattern may
differ between patients: female patients typically require between
15 and 20 units of Botox to adequately treat the corrugator and
procerusmuscles. Male patients and females with large corrugators
often require larger doses. Once the injections are completed,
pressure is applied to the target sites for 5–10 min to minimize
bruising. Ice packs and cold compresses can also be used. Patients
are advised that the full effect may not be evident for 10–14 days. If
necessary, supplemental injections can be performed to achieve the
desired result.
3.3. Effectiveness
Lower doses should therefore be associated with a decreased
incidence of adverse effect. Lower doses also result in diminished
cost to the patient. With good technique, precision, and attention to
detail, we feel that we can obtain equivalent cosmetic results, with
less risk and at a lower cost to the patient.
3.4. Complications
Complications from facial Botox injections are rare. The most
common adverse consequences are lack of effect, injection site
reaction, and the rare risk of eyelid ptosis if Botox diffuses into the
orbit.32
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Not every interventional radiologist should or would want to
enter into cosmetic medicine. Advantages of cosmetic IR treat-
ments are many: treatments takes less than an hour and provides
immediate relief of symptoms; no scaring, because the procedure
does not require a surgical incision, just a nick in the skin, about the
size of a pencil tip; an immediate return to normal activity with
little or no pain; and high success rate and low recurrence rate
compared to surgery. IR treatments are a valide alternative to
surgery, but not a substitute. Every treatment decision is always
taken according to surgeon.Conﬂict of interest
None.
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